Detailed Information on Publication Record

@proceedings{60359,
   author = {Hlaváč, Kryštof and Ondrišová, Laura and Šeda, Václav and Hoferková, Eva and Chiodin, G. and Košťálová, Lenka and Mladonická Pavlasová, Gabriela and Filip, Daniel and Faria Zeni, Pedro and Oppelt, Jan and Panovská, Anna and Plevová, Karla and Pospíšilová, Šárka and Šimkovič, M. and Vrbacký, F. and Lysák, Daniel and Fernandes, SM. and Davids, MS. and MaiquesandDiaz, A. and Charalampopoulou, S. and MartinandSubero, I. and Brown, JR. and Doubek, Michael and Forconi, Francesco and Mayer, Jiří and Mráz, Marek},
   booktitle = {Czech Annual Cancer Research Meeting, Olomouc},
   keywords = {BCR inhibitors; CLL; PI3K-Akt activation},
   language = {eng},
   title = {Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.},
   url = {https://cancermeeting.cz/czech-annual-cancer-research-meeting-2023/},
   year = {2023}
}

TY  - CONF
ID  - 60359
AU  - Hlaváč, Kryštof - Ondrišová, Laura - Šeda, Václav - Hoferková, Eva - Chiodin, G. - Košťálová, Lenka - Mladonická Pavlasová, Gabriela - Filip, Daniel - Faria Zeni, Pedro - Oppelt, Jan - Panovská, Anna - Plevová, Karla - Pospíšilová, Šárka - Šimkovič, M. - Vrbacký, F. - Lysák, Daniel - Fernandes, SM. - Davids, MS. - Maiques-Diaz, A. - Charalampopoulou, S. - Martin-Subero, I. - Brown, JR. - Doubek, Michael - Forconi, Francesco - Mayer, Jiří - Mráz, Marek
PY  - 2023
TI  - Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.
KW  - BCR inhibitors
KW  - CLL
KW  - PI3K-Akt activation
UR  - https://cancermeeting.cz/czech-annual-cancer-research-meeting-2023/
N2  - Genetic resistance mechanisms to BCR inhibitors in CLL have been extensively described, but it remains unclear whether non-genetic adaptation might exist in CLL cells allowing for lasting lymphocytosis or resistance. We focused on the possible role of the Akt pathway in adapting to BCR inhibitors since, in mouse models, PI3K-Akt activation is the only known factor that rescues the apoptosis induced by BCR deletion in mature B cells.
ER  - 

HLAVÁČ, Kryštof, Laura ONDRIŠOVÁ, Václav ŠEDA, Eva HOFERKOVÁ, G. CHIODIN, Lenka KOŠŤÁLOVÁ, Gabriela MLADONICKÁ PAVLASOVÁ, Daniel FILIP, Pedro FARIA ZENI, Jan OPPELT, Anna PANOVSKÁ, Karla PLEVOVÁ, Šárka POSPÍŠILOVÁ, M. ŠIMKOVIČ, F. VRBACKÝ, Daniel LYSÁK, SM. FERNANDES, MS. DAVIDS, A. MAIQUES-DIAZ, S. CHARALAMPOPOULOU, I. MARTIN-SUBERO, JR. BROWN, Michael DOUBEK, Francesco FORCONI, Jiří MAYER and Marek MRÁZ. Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia. In \textit{Czech Annual Cancer Research Meeting, Olomouc}. 2023.